Alnylam Pharmaceuticals annual revenue
2008
2009
2010
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Alnylam Pharmaceuticals Revenue Growth & History (ALNY)
Alnylam Pharmaceuticals reported $3.71B in revenue for fiscal 2025, an increase of 65.19% from the previous fiscal year.
View full Alnylam Pharmaceuticals company overviewAlnylam Pharmaceuticals annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.71B | $1.47B | +65.19% |
| 2024 | 2024-12-31 | $2.25B | $420.0M | +22.97% |
| 2023 | 2023-12-31 | $1.83B | $790.9M | +76.23% |
| 2022 | 2022-12-31 | $1.04B | $193.1M | +22.88% |
| 2021 | 2021-12-31 | $844.3M | $351.4M | +71.31% |
| 2020 | 2020-12-31 | $492.9M | $273.1M | +124.28% |
| 2019 | 2019-12-31 | $219.8M | $144.8M | +193.36% |
| 2018 | 2018-12-31 | $74.9M | −$15.0M | −16.69% |
| 2017 | 2017-12-31 | $89.9M | $42.8M | +90.66% |
| 2016 | 2016-12-31 | $47.2M | — | — |
| 2010 | 2010-12-31 | $100.0M | −$492,000 | −0.49% |
| 2009 | 2009-12-31 | $100.5M | $4.4M | +4.54% |
| 2008 | 2008-12-31 | $96.2M | — | — |
Alnylam Pharmaceuticals quarterly revenue
Q2.09
Q3.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q1.17
Q2.17
Q3.17
Q4.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.29B | $517.3M | +66.86% |
| Q1 2026 | 2026-03-31 | $1.17B | $573.0M | +96.43% |
| Q4 2025 | 2025-12-31 | $1.10B | $503.9M | +84.95% |
| Q3 2025 | 2025-09-30 | $1.25B | $748.1M | +149.35% |
| Q2 2025 | 2025-06-30 | $773.7M | $113.9M | +17.26% |
| Q1 2025 | 2025-03-31 | $594.2M | $99.9M | +20.20% |
| Q4 2024 | 2024-12-31 | $593.2M | $153.4M | +34.90% |
| Q3 2024 | 2024-09-30 | $500.9M | −$249.6M | −33.26% |
| Q2 2024 | 2024-06-30 | $659.8M | $341.1M | +107.00% |
| Q1 2024 | 2024-03-31 | $494.3M | $175.0M | +54.82% |
| Q4 2023 | 2023-12-31 | $439.7M | $104.7M | +31.25% |
| Q3 2023 | 2023-09-30 | $750.5M | $486.2M | +183.96% |
| Q2 2023 | 2023-06-30 | $318.8M | $93.9M | +41.78% |
| Q1 2023 | 2023-03-31 | $319.3M | $106.0M | +49.72% |
| Q4 2022 | 2022-12-31 | $335.0M | $76.5M | +29.59% |
| Q3 2022 | 2022-09-30 | $264.3M | $76.7M | +40.86% |
| Q2 2022 | 2022-06-30 | $224.8M | $4.3M | +1.93% |
| Q1 2022 | 2022-03-31 | $213.3M | $35.7M | +20.10% |
| Q4 2021 | 2021-12-31 | $258.5M | $95.0M | +58.07% |
| Q3 2021 | 2021-09-30 | $187.6M | $61.8M | +49.09% |
| Q2 2021 | 2021-06-30 | $220.6M | $116.6M | +112.15% |
| Q1 2021 | 2021-03-31 | $177.6M | $78.1M | +78.50% |
| Q4 2020 | 2020-12-31 | $163.6M | $91.9M | +128.18% |
| Q3 2020 | 2020-09-30 | $125.9M | $55.8M | +79.63% |
| Q2 2020 | 2020-06-30 | $104.0M | $59.2M | +132.50% |
| Q1 2020 | 2020-03-31 | $99.5M | $66.2M | +198.78% |
| Q4 2019 | 2019-12-31 | $71.7M | $50.6M | +240.80% |
| Q3 2019 | 2019-09-30 | $70.1M | $68.0M | +3286.23% |
| Q2 2019 | 2019-06-30 | $44.7M | $14.8M | +49.51% |
| Q1 2019 | 2019-03-31 | $33.3M | $11.4M | +52.03% |
| Q4 2018 | 2018-12-31 | $21.0M | — | — |
| Q3 2018 | 2018-09-30 | $2.1M | −$15.0M | −87.90% |
| Q2 2018 | 2018-06-30 | $29.9M | $14.0M | +87.72% |
| Q1 2018 | 2018-03-31 | $21.9M | $2.9M | +15.50% |
| Q4 2017 · Jan 1 | 2018-01-01 | $2.9M | — | — |
| Q4 2017 | 2017-12-31 | $37.9M | — | — |
| Q3 2017 | 2017-09-30 | $17.1M | — | — |
| Q2 2017 | 2017-06-30 | $15.9M | — | — |
| Q1 2017 | 2017-03-31 | $19.0M | — | — |
| Q1 2011 | 2011-03-31 | $20.9M | −$3.7M | −14.93% |
| Q4 2010 | 2010-12-31 | $21.2M | — | — |
| Q3 2010 | 2010-09-30 | $27.7M | $3.4M | +14.10% |
| Q2 2010 | 2010-06-30 | $26.6M | $2.0M | +8.19% |
| Q1 2010 | 2010-03-31 | $24.6M | — | — |
| Q3 2009 | 2009-09-30 | $24.2M | — | — |
| Q2 2009 | 2009-06-30 | $24.6M | — | — |
Alnylam Pharmaceuticals revenue growth trends
Over the last five reported fiscal years, revenue grew from $492.9M to $3.71B, a compound annual growth rate of 49.77%. Alnylam Pharmaceuticals's latest reported quarter, Q2 2026, generated $1.29B in revenue, an increase of 66.86% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Alnylam Pharmaceuticals source filings ↗